Drug developers face great pressures to complete clinical trials on time and on budget, but challenges like patient recruitment, patient retention, and site selection can cause unexpected delays with significant economic consequences. This is particularly true in the area of rare disease drug development where patient populations are small and geographically dispersed. Arthur D. Little […]